Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors

NCT02016534 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
60
Enrollment
INDUSTRY
Sponsor class

Stopped Amgen decision following interim review of efficacy and safety data from the AMG 337 program.

Conditions

Interventions

Sponsor

Amgen